IMPT Dose Escalation for NSCLC (HyDose)

The goal of this clinical pilot trial is to learn if dose to the tumor in the lung can be safely increased using proton therapy in stage III non-small-cell lung cancer patients receiving combined chemotherapy and radiotherapy. The main questions it aims to answer are: * Is the risk of severe radiotherapy toxicities (requiring hospital admission) within acceptable margins ? * What is a rough estimate of the effect of the treatment under study? Compared to standard care in our clinic, all participants in this pilot trial will * Receive a higher dose of proton therapy to the tumor in the lung

Trial Details

NCT ID
NCT06484491
Phase
NA
Sponsor
University Medical Center Groningen
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • Dose-escalated intensity-modulated proton therapy (IMPT-74)
  • Cisplatin or carboplatin + pemetrexed for induction chemotherapy, cisplatin + docetaxel for concurrent chemotherapy
  • Immunotherapy: adjuvant durvalumab
Locations (sample)
  • Groningen, Netherlands|53.21917,6.56667

Key Eligibility Criteria

  • Age ≥18 years
  • WHO performance score 0-2
  • Histologically proven stage III NSCLC
  • Planned for CCRT and adjuvant immunotherapy (intention to treat)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →